BPIM
BIO icon

Brant Point Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Brant Point Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,500
Closed -$4.11M – 135
2024
Q4 		$4.11M Buy
+12,500
New +$4.24M 0.51% 60

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brant Point Investment Management's BIO Position: Q1 2025 in Review

Brant Point Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 12,500 shares — an estimated $4.11M sold.

Brant Point Investment Management first reported a position in BIO in Q4 2024 and held it in 1 quarter. The position peaked at $4.11M in Q4 2024. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Brant Point Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Brant Point Investment Management sold 12,500 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $4.11M.
  • Brant Point Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and held it in 1 quarter.
  • Brant Point Investment Management's Bio-Rad Laboratories Class A position peaked at $4.11M in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Brant Point Investment Management's 13F filing for Q1 2025, filed 14 May 2025.